Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.54 |
| ▸ | DHODH | Q02127 | 2/20 | 0.54 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.53 |
| ▸ | ESR1 | P03372 | 2/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.51 |
| ▸ | ESRRB | O95718 | 1/20 | 0.51 |
| ▸ | ESRRA | P11474 | 1/20 | 0.51 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | ACACA | Q13085 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26075536 | 0.95 | PLA2G2A (0.53) | PDE10ADHODHPLA2G2AESR1ESR2 | |
| SCHEMBL26075544 | 0.93 | PLA2G2A (0.51) | PDE10ADHODHPLA2G2AESR1ESR2 | |
| SCHEMBL26075556 | 0.92 | PLA2G2A (0.50) | PDE10ADHODHPLA2G2AESR1ESR2 | |
| SCHEMBL26075537 | 0.92 | PLA2G2A (0.50) | PDE10ADHODHPLA2G2AESR1ESR2 | |
| SCHEMBL26074112 | 0.91 | PLA2G2A (0.49) | PDE10ADHODHPLA2G2AESR1ESR2 | |
| SCHEMBL26075529 | 0.90 | ESR1 (0.53) | DHODHPLA2G2AESR1ESR2ESRRB | |
| SCHEMBL26074127 | 0.90 | ESR1 (0.48) | PDE10ADHODHPLA2G2AESR1ESR2 | |
| SCHEMBL26075533 | 0.86 | PLA2G2A (0.63) | DHODHPLA2G2AESR1ESR2ESRRB | |
| SCHEMBL26075540 | 0.86 | ESR1 (0.49) | PDE10ADHODHPLA2G2AESR1ESR2 | |
| SCHEMBL23590068 | 0.85 | DHODH (0.74) | PDE10ADHODHPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | PDE10A 3462/4885DHODH 1/4885PLA2G2A 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.